CL2003002588A1 - Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t - Google Patents

Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t

Info

Publication number
CL2003002588A1
CL2003002588A1 CL200302588A CL2003002588A CL2003002588A1 CL 2003002588 A1 CL2003002588 A1 CL 2003002588A1 CL 200302588 A CL200302588 A CL 200302588A CL 2003002588 A CL2003002588 A CL 2003002588A CL 2003002588 A1 CL2003002588 A1 CL 2003002588A1
Authority
CL
Chile
Prior art keywords
barbituric acid
metoximetildifenil
dimetoximetildifenil
difenil
prepare
Prior art date
Application number
CL200302588A
Other languages
English (en)
Inventor
Daniel Moros
Original Assignee
Taro Pharmaceuticals Ireland L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceuticals Ireland L filed Critical Taro Pharmaceuticals Ireland L
Publication of CL2003002588A1 publication Critical patent/CL2003002588A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL200302588A 2002-12-11 2003-12-11 Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t CL2003002588A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43247002P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
CL2003002588A1 true CL2003002588A1 (es) 2005-01-07

Family

ID=32507936

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200302588A CL2003002588A1 (es) 2002-12-11 2003-12-11 Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t

Country Status (17)

Country Link
US (3) US7166610B2 (es)
EP (2) EP1569627B1 (es)
JP (1) JP4739760B2 (es)
CN (2) CN101569626B (es)
AR (1) AR042444A1 (es)
AT (1) ATE413867T1 (es)
AU (2) AU2003302897C1 (es)
BR (1) BR0317289A (es)
CA (1) CA2505335C (es)
CL (1) CL2003002588A1 (es)
DE (1) DE60324703D1 (es)
ES (1) ES2315569T3 (es)
IL (1) IL168853A (es)
MX (1) MXPA05006271A (es)
PT (1) PT1569627E (es)
TW (2) TWI334780B (es)
WO (1) WO2004052350A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
CA2505335C (en) 2002-12-11 2013-09-10 Daniel Aaron Moros Method of treating movement disorders using barbituric acid derivatives
WO2006003651A2 (en) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
US9056817B2 (en) * 2011-09-12 2015-06-16 Council Of Scientific And Industrial Research Arylated β-dicarbonyl compounds and process for the preparation thereof
IT201700059814A1 (it) * 2017-05-31 2018-12-01 Antonio Costantini Vitamina b1 in alte dosi per uso nel trattamento medico di alcune malattie neurodegenerative sporadiche , di origine genetica e delle cefalee primarie

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1960170A (en) 1934-05-22 Cc - phenylethyl - n -
US2119701A (en) 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
US2673205A (en) 1951-02-13 1954-03-23 Ciba Pharm Prod Inc 3-disubstituted dioxopiperidines and the manufacture thereof
DE946804C (de) 1952-02-28 1956-08-09 Emanuel Merck Ohg Verfahren zur Herstellung von schwefelhaltigen Abkoemmlingen der Barbitursaeure
DE1103339B (de) 1959-02-04 1961-03-30 Chemische Werke Radebeul Veb Verfahren zur Herstellung von in 5-Stellung crotylierten, basisch substituierten Barbitursaeure-derivaten
DE1100639B (de) 1959-03-24 1961-03-02 Chemische Werke Radebeul Veb Verfahren zur Herstellung von basisch substituierten Barbitursaeure-derivaten
GB966098A (en) 1959-11-23 1964-08-06 Sapos Sa Barbiturate derivatives
US3930006A (en) * 1963-04-30 1975-12-30 Aspro Nicholas Ltd Antiparkinsonism compositions and method
US4046894A (en) 1968-08-05 1977-09-06 Bristol-Myers Company Certain barbituric acid derivatives used as anticonvulsant agents
US3679683A (en) 1970-05-11 1972-07-25 Exxon Research Engineering Co Barbiturate 3-n-methylene phosphates
US3711607A (en) 1971-03-17 1973-01-16 Kendall & Co N,n -dihalomethyl phenobarbital for the treatment of convulsions
US3904627A (en) 1972-06-02 1975-09-09 Kendall & Co 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3919427A (en) 1972-06-02 1975-11-11 Kendall & Co Therapeutic compositions containing 1-methyl-3-alkoxymethyl-5,5-disubstituted barbituric acid compounds
US3900475A (en) 1972-06-26 1975-08-19 Kendall & Co Certain phenobarbital salts
US3948896A (en) 1973-02-28 1976-04-06 The Kendall Company N-mono(alkoxymethyl) phenobarbitals, process therefor and therapeutic composition and method containing same
US4060528A (en) 1975-10-08 1977-11-29 Janssen Pharmaceutica N.V. Aroyl-substituted phenylmalonic acid derivatives
US4029662A (en) 1976-04-30 1977-06-14 Bristol-Myers Company Method of making barbituric acid derivatives
DE2622981A1 (de) 1976-05-21 1977-12-08 Unisearch Ltd Verfahren zur herstellung von halogenalkylierten verbindungen
US4260769A (en) 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
DE3374684D1 (en) 1982-08-31 1988-01-07 Daikin Ind Ltd A method to trap the enolate ion of the malonic acid or its derivatives
IL69722A (en) 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4631294A (en) * 1985-07-05 1986-12-23 University E.M., Inc. Treatment of cerebral ischemia with dichloroacetate
IT1196500B (it) 1986-07-16 1988-11-16 Eniricerche Spa Derivati dell'acido malonico e metodi per la loro sintesi
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
US4833148A (en) 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
DE4028040A1 (de) 1990-09-05 1992-03-12 Chemie Linz Deutschland Verfahren zur n-alkylierung von harnstoffen
US5456851A (en) 1994-04-07 1995-10-10 Johnson & Johnson Consumer Products, Inc. Ketoconazole shampoo containing butylated hydroxytoluene or butylated hydroxyanisole
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
DE19504623A1 (de) 1995-02-13 1996-08-14 Bayer Ag Verfahren zur Herstellung von N-substituierten cyclischen Imiden
RU2147584C1 (ru) 1995-10-27 2000-04-20 Американ Цианамид Компани Способ получения дигалоидазолопиримидинов и способ получения дигидроксиазолопиримидинов
KR100194535B1 (ko) 1995-12-27 1999-06-15 우종일 아릴 벤조일 우레아 유도체 및 이를 함유하는 농약조성물
CA2276042C (en) 1996-12-26 2002-10-08 Michika Takano N-hydroxyurea derivatives and medicinal compositions containing the same
US5756815A (en) 1997-03-18 1998-05-26 American Cyanamid Company Process for the preparation arylamalonates
US5750766A (en) 1997-03-18 1998-05-12 American Cyanamid Company Process for the preparation of arylmalonates
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US5985856A (en) 1997-12-31 1999-11-16 University Of Kansas Water soluble prodrugs of secondary and tertiary amine containing drugs and methods of making thereof
AU4037799A (en) 1998-05-08 1999-11-29 Smithkline Beecham Plc Phenylurea and phenylthio urea derivatives
US7074925B1 (en) 1998-05-26 2006-07-11 Rimma Lliinichna Ashkinazi N-substituted derivatives of 5-oxyiminobarbituric acid
US6156925A (en) 1998-09-25 2000-12-05 American Cyanamid Company Process for the preparation of halogenated phenylmaloates
US7214658B2 (en) * 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
US6262067B1 (en) 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
EP1244456B1 (en) * 1999-12-01 2007-05-09 Ucb, S.A. A pyrrolidineacetamide derivative for treatment of chronic or neuropathic pain
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
CA2306170A1 (en) 2000-04-18 2001-10-18 Kenneth Curry Novel amino, carboxy derivatives of barbituric acid
CN100522172C (zh) * 2000-07-26 2009-08-05 塔罗制药工业有限公司 非镇静巴比土酸盐化合物在制备神经保护剂中的用途
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
JP2005516052A (ja) 2002-01-30 2005-06-02 タロ ファーマシューティカル インダストリーズ リミテッド 非鎮静性バルビツール酸誘導体
CA2505335C (en) 2002-12-11 2013-09-10 Daniel Aaron Moros Method of treating movement disorders using barbituric acid derivatives
WO2006003651A2 (en) 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP1625848A1 (en) 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES

Also Published As

Publication number Publication date
US20040186120A1 (en) 2004-09-23
JP2006510659A (ja) 2006-03-30
BR0317289A (pt) 2005-11-08
EP2156839A1 (en) 2010-02-24
JP4739760B2 (ja) 2011-08-03
EP1569627B1 (en) 2008-11-12
WO2004052350A3 (en) 2004-09-23
US20100311771A1 (en) 2010-12-09
AU2003302897C1 (en) 2010-07-08
AU2010200787A1 (en) 2010-03-25
CN1717235A (zh) 2006-01-04
MXPA05006271A (es) 2006-01-30
CN101569626A (zh) 2009-11-04
IL168853A (en) 2011-07-31
DE60324703D1 (de) 2008-12-24
US8314115B2 (en) 2012-11-20
TWI334780B (en) 2010-12-21
CN100502871C (zh) 2009-06-24
ATE413867T1 (de) 2008-11-15
CA2505335A1 (en) 2004-06-24
PT1569627E (pt) 2009-01-20
US20070072886A1 (en) 2007-03-29
EP1569627A2 (en) 2005-09-07
AR042444A1 (es) 2005-06-22
TW200822927A (en) 2008-06-01
WO2004052350A2 (en) 2004-06-24
AU2003302897B2 (en) 2009-12-03
ES2315569T3 (es) 2009-04-01
CA2505335C (en) 2013-09-10
US7166610B2 (en) 2007-01-23
AU2003302897A1 (en) 2004-06-30
US7776871B2 (en) 2010-08-17
TW200418481A (en) 2004-10-01
CN101569626B (zh) 2012-02-08

Similar Documents

Publication Publication Date Title
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
BRPI0311275A2 (pt) "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
ECSP045491A (es) Nueva sal formiato de o-desmetil venlafaxina
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
CL2004000303A1 (es) Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
ATE372765T1 (de) Feste pharmazeutische formulierungen mit telmisartan
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR049274A1 (es) Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
AR012125A1 (es) UNA SAL DE UN COMPUESTO DERIVADO DEL ÁCIDO NAFTIRIDINA CARBOXíLICO , SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO , PROCEDIMIENTO PARA PREPARARLA Y UNA COMPOSICIoN FARMACÉUTICA QUE LO COMPRENDE
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
ITMI20020189A0 (it) Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
PT1560826E (pt) Compostos piridopirimidinona, seus processos de preparacao e composicoes farmaceuticas que os contem